Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multicenter Trial of Pediatric Autologous Bone Marrow Mononuclear Cells (BMMNCs) for Severe Traumatic Brain Injury (TBI)

Trial Profile

A Phase 2 Multicenter Trial of Pediatric Autologous Bone Marrow Mononuclear Cells (BMMNCs) for Severe Traumatic Brain Injury (TBI)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs CEVA 101 (Primary)
  • Indications Traumatic brain injuries
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Apr 2018 New trial record
    • 16 Mar 2018 This study is supported by the National Institutes of Health (NIH) and Department of Defense grant.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top